These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22369367)

  • 1. Relationships between exploratory eye movement dysfunction and clinical symptoms in schizophrenia.
    Suzuki M; Takahashi S; Matsushima E; Tsunoda M; Kurachi M; Okada T; Hayashi T; Ishii Y; Morita K; Maeda H; Katayama S; Otsuka T; Hirayasu Y; Sekine M; Okubo Y; Motoshita M; Ohta K; Uchiyama M; Kojima T
    Psychiatry Clin Neurosci; 2012 Apr; 66(3):187-94. PubMed ID: 22369367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of exploratory eye movement in schizophrenia patients and their siblings.
    Takahashi S; Tanabe E; Yara K; Matsuura M; Matsushima E; Kojima T
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):487-93. PubMed ID: 18950366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements.
    Mikami T; Naruse N; Fukura Y; Ohkubo H; Ohkubo T; Matsuura M; Moriya H; Nishikawa T; Kojima T
    Psychiatry Clin Neurosci; 2003 Aug; 57(4):433-40. PubMed ID: 12839526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eye tracking performance and the boundaries of the schizophrenia spectrum.
    Mitropoulou V; Friedman L; Zegarelli G; Wajnberg S; Meshberg J; Silverman JM; Siever LJ
    Psychiatry Res; 2011 Mar; 186(1):18-22. PubMed ID: 20826004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Eye movements in schizophrenia--relationships among eye movements under three experimental conditions; closed-eye, pursuit, and exploratory].
    Nakajima K
    Seishin Shinkeigaku Zasshi; 1990; 92(8):509-31. PubMed ID: 2236349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between exploratory eye movement, P300, and reaction time in schizophrenia.
    Takahashi S; Tanabe E; Sakai T; Matsuura M; Matsushima E; Obayashi S; Kojima T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):396-403. PubMed ID: 18778436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory eye movements during the Benton Visual Retention Test: characteristics of visual behavior in schizophrenia.
    Obayashi S; Matsushima E; Ando H; Ando K; Kojima T
    Psychiatry Clin Neurosci; 2003 Aug; 57(4):409-15. PubMed ID: 12839523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Arango C; Bernardo M
    Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics of chronic schizophrenic patients presenting with severe anhedonia].
    Loas G; Noisette C; Legrand A; Boyer P; Delahousse J
    Encephale; 1996; 22(5):351-8. PubMed ID: 9035991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory eye movement dysfunctions in patients with schizophrenia: possibility as a discriminator for schizophrenia.
    Matsushima E; Kojima T; Ohta K; Obayashi S; Nakajima K; Kakuma T; Ando H; Ando K; Toru M
    J Psychiatr Res; 1998; 32(5):289-95. PubMed ID: 9789207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
    Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
    Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
    Huguelet P; Nicastro R; Zanello A
    Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of panic attacks and hostility in chronic schizophrenia.
    Chen CY; Liu CY; Yang YY
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):383-7. PubMed ID: 11442890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory eye movement dysfunction as a discriminator for schizophrenia : a large sample study using a newly developed digital computerized system.
    Suzuki M; Takahashi S; Matsushima E; Tsunoda M; Kurachi M; Okada T; Hayashi T; Ishii Y; Morita K; Maeda H; Katayama S; Kawahara R; Otsuka T; Hirayasu Y; Sekine M; Okubo Y; Motoshita M; Ohta K; Uchiyama M; Kojima T
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):186-94. PubMed ID: 19165524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.